share_log

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376

Canaccord Genuity維持賣出福泰製藥的評級,並將價格目標上調至376美元。
Benzinga ·  07/31 08:38  · 評級/大行評級

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sell and raises the price target from $371 to $376.

Canaccord Genuity分析師Whitney Ijem認爲福泰製藥(NASDAQ:VRTX)是賣出,並將價格目標從371美元上調至376美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論